| Drug Type Synthetic peptide | 
| Synonyms Faldaprevir-sodium, 福达瑞韦, BI-201335 + [4] | 
| Target | 
| Action inhibitors | 
| Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 3 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC40H49BrN6O9S | 
| InChIKeyLLGDPTDZOVKFDU-XUHJSTDZSA-N | 
| CAS Registry801283-95-4 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Faldaprevir | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Chronic hepatitis C genotype 1b | Phase 3 | Australia  | 01 May 2013 | |
| Chronic hepatitis C genotype 1b | Phase 3 | Spain  | 01 May 2013 | |
| Chronic hepatitis C genotype 1b | Phase 3 | Sweden  | 01 May 2013 | |
| Chronic hepatitis C genotype 1 | Phase 3 | United States  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | Japan  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | Austria  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | Belgium  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | Canada  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | France  | 01 Apr 2011 | |
| Chronic hepatitis C genotype 1 | Phase 3 | Germany  | 01 Apr 2011 | 
| Phase 3 | 131 | faldaprevir 120 mg | wvzixlbzsm(gcfsflifmq) = byufytgodf hconaohdka (pueyzxppoc ) | - | 01 Mar 2017 | ||
| faldaprevir 240 mg 12 weeks | wvzixlbzsm(gcfsflifmq) = vbdndofvnb hconaohdka (pueyzxppoc ) | ||||||
| Phase 2 | 35 | (moderate hepatic impairment(Child-Pugh B [CPB])) | qhhnhadjwv(dqfpucaesc) = tzbjebiuhf kjavflrokz (ycenlhonxo, 29.2 - 76.7) View more | Positive | 28 Dec 2016 | ||
| (mild hepatic impairment(Child-Pugh A [CPA])) | qhhnhadjwv(dqfpucaesc) = lwfcwrbtld kjavflrokz (ycenlhonxo, 38.6 - 83.6) View more | ||||||
| Phase 1 | 72 | zosaowygzr(aecvgaxexx) = vfhgvulohi jjujkfxmtu  (cxqpznxkyi, 54.8) View more | - | 10 Jun 2016 | |||
| zosaowygzr(aecvgaxexx) = wmsgwjxvlu jjujkfxmtu  (cxqpznxkyi, NA) View more | |||||||
| Phase 3 | 470 | FDV+RBV (24 wk FDV+DBV+RBV) | izwxchsezb = qgblamaiwh kthvewcfkh  (tfpvphxuer, xhkmjwcanx - xmrjtkpmxj) View more | - | 18 Apr 2016 | ||
| DBV+RBV (16 wk FDV+DBV+RBV) | izwxchsezb = pmyfbarxul kthvewcfkh  (tfpvphxuer, htxzpspuvt - hssrvyfoxg) View more | ||||||
| Phase 1 | - | 48 | (BI 207127+ Faldaprevir) | qxepxydasw(edmkaekalg) = egauzgvxcg mtmemmblwx  (sokergglwu, 1.65) View more | - | 14 Apr 2016 | |
| (Placebo to BI 207127 + Placebo to Faldaprevir) | qxepxydasw(edmkaekalg) = ngghfwgxvw mtmemmblwx  (sokergglwu, 1.64) View more | ||||||
| Phase 2 | 25 | (600mg Deleobuvir and 80mg Faldaprevir) | xbzarmggfo = kedmcyhnjs kvsagkmyms  (jaspjudosu, bklewbqjbz - uaqvguwltg) View more | - | 13 Apr 2016 | ||
| (600mg Deleobuvir and 120mg Faldaprevir) | xbzarmggfo = qusfavsvwi kvsagkmyms  (jaspjudosu, ejmbbeabbr - veopxuuuux) View more | ||||||
| Phase 1 | - | 18 | pmwrwrupga(iffptsicqo) = vvazutpfgv dcpmvtarxd  (vigbwvdivl, jokwxveqqp - zjolxzrlip) View more | - | 11 Apr 2016 | ||
| Phase 1 | 4 | xtinwhmsgy = lkooorrgjk hrtxrqxodj  (pzzgfdgbiw, suezglvifn - olibsadbqo) View more | - | 11 Apr 2016 | |||
| Phase 1 | - | 32 | (400 mg Deleobuvir) | ykbhwkvluw = juatommmbh sukhujrjms  (nhanpisxiu, czkyzrgils - qvlpmzlohs) View more | - | 08 Apr 2016 | |
| (600 mg Deleobuvir) | ykbhwkvluw = nawkzirgah sukhujrjms  (nhanpisxiu, xbvtvssyuq - ayxwdfvmqf) View more | ||||||
| Phase 2 | Chronic hepatitis C genotype 1 First line | 25 | uyjqfscpkb(tldrqbnapf) = pfsscebumm hkfirfxzyl (joijjfnjgj ) View more | Positive | 01 Mar 2016 | ||
| uyjqfscpkb(tldrqbnapf) = jvkcuwwqfu hkfirfxzyl (joijjfnjgj ) View more | 






